By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Company, Ltd. 

4-6-10 Koishikawa, Bunkyo-ku

Tokyo    112-8088  Japan
Phone: 81-3-3817-3700 Fax: n/a


SEARCH JOBS


Key Statistics


Email: webmaster@eisai.co.jp
Ownership: Public

Web Site: Eisai Company
Employees: 7,043
Symbol: ESALY.PK
 









Company News
Eisai Company (ESALY.PK) Release: Anticancer Agent "Treakisym For Injection 100 Mg" Approved In Japan For Additional Indication Of Chronic Lymphocytic Leukemia 8/26/2016 8:42:00 AM
Eisai Company (ESALY.PK) Release: U.S. FDA Confirms Sufficient Data To Advance Investigational Bace Inhibitor E2609 For Treatment Of Early Alzheimer’s Disease To PHASE III 8/10/2016 6:46:27 AM
Eisai Company (ESALY.PK) Presents Results Of Additional Analysis Of Phase III Study Of Anticancer Agent Halaven At 14th JSMO Annual Meeting Plenary Session 8/1/2016 10:36:06 AM
AbbVie (ABBV), Eisai Company (ESALY.PK), And EA Pharma Obtain Additional Approval For New Dosing Regimen Of Fully Human Anti-TNF Monoclonal Antibody Humira In Patients With Crohn's Disease 6/20/2016 9:55:54 AM
Eisai Company (ESALY.PK) Launches New Oral Suspension Formulation For Antiepileptic Drug Fycompa (Perampanel) In The United States 6/16/2016 10:30:33 AM
Eisai Company (ESALY.PK) To Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) 5/25/2016 9:56:37 AM
Eisai Company (ESALY.PK) Beefs Up Neurology Team with Ex-Pfizer (PFE), Sanofi (SNY) Execs 4/22/2016 7:13:18 AM
Eisai Company (ESALY.PK) Release: Aricept Approved In The Philippines For New Indication As Treatment For Dementia With Lewy Bodies 4/14/2016 9:23:12 AM
Dr. Reddy's Laboratories Ltd. (RDY) Inks Licensing Pact with Japan's Eisai Company (ESALY.PK) for Anti-Cancer Agent 3/31/2016 6:08:26 AM
As part of Eisai Company (ESALY.PK)’s Strategic Plan, Morphotek Subsidiary Cuts 27 Jobs as Part of Restructuring 3/23/2016 7:08:03 AM
12345678910...
//-->